Adaptive radiation aims to outsmart aggressive brain tumors
NCT ID NCT05720078
First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time
Summary
This study tests whether a personalized, two-phase radiation therapy approach can better control glioblastoma, an aggressive brain cancer. The treatment adapts the radiation plan based on tumor changes during therapy, potentially targeting the tumor more precisely while sparing healthy tissue. Researchers will compare local control, survival, and side effects between this adaptive method and standard radiation in 70 adults with newly diagnosed glioblastoma.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- adaptive radiation therapy
- What this could lead to
- If successful, this approach could improve local tumor control and reduce side effects for people with glioblastoma.
- What could go wrong
- This is a relatively small, early-phase study, so results may not apply broadly. The adaptive technique is complex and may not improve outcomes over standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME, ADULT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sunnybrook Health Sciences Centre
Toronto, Ontario, M4N3M5, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Electric fields plus targeted radiation may boost survival in recurrent glioblastoma
- Brain cancer breakthrough? new trial delivers drug straight to tumor
- Surgical flap may open door to better brain tumor treatment
- New drug combo shows promise in tough brain cancer
- New radiation boost shows promise for elderly glioblastoma patients
- New hope for glioblastoma: experimental drug berubicin faces key trial